JPWO2020244654A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020244654A5 JPWO2020244654A5 JP2021572340A JP2021572340A JPWO2020244654A5 JP WO2020244654 A5 JPWO2020244654 A5 JP WO2020244654A5 JP 2021572340 A JP2021572340 A JP 2021572340A JP 2021572340 A JP2021572340 A JP 2021572340A JP WO2020244654 A5 JPWO2020244654 A5 JP WO2020244654A5
- Authority
- JP
- Japan
- Prior art keywords
- met
- cancer
- alkyl
- gene
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019090294 | 2019-06-06 | ||
| CNPCT/CN2019/090294 | 2019-06-06 | ||
| CN2019092706 | 2019-06-25 | ||
| CNPCT/CN2019/092706 | 2019-06-25 | ||
| CN2019109906 | 2019-10-08 | ||
| CNPCT/CN2019/109906 | 2019-10-08 | ||
| PCT/CN2020/094824 WO2020244654A1 (en) | 2019-06-06 | 2020-06-08 | Method for treating cancer patients using c-met inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535880A JP2022535880A (ja) | 2022-08-10 |
| JPWO2020244654A5 true JPWO2020244654A5 (https=) | 2023-06-15 |
| JP2022535880A5 JP2022535880A5 (https=) | 2023-06-15 |
Family
ID=73653139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572340A Pending JP2022535880A (ja) | 2019-06-06 | 2020-06-08 | ｃ－ＭＥＴ阻害剤を使用して癌患者を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220252603A1 (https=) |
| EP (1) | EP3980783A4 (https=) |
| JP (1) | JP2022535880A (https=) |
| CN (1) | CN114599978A (https=) |
| CA (1) | CA3142642A1 (https=) |
| WO (1) | WO2020244654A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112592976B (zh) * | 2020-12-30 | 2021-09-21 | 深圳市海普洛斯生物科技有限公司 | 一种检测met基因扩增的方法及装置 |
| MX2023012434A (es) * | 2021-04-21 | 2024-02-08 | Apollomics Inc | Diagnostico y tratamiento de cancer usando inhibidor de c-met. |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008113013A2 (en) * | 2007-03-15 | 2008-09-18 | University Of Chicago | C-met mutations and uses thereof |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| KR20130103734A (ko) * | 2010-08-31 | 2013-09-24 | 제넨테크, 인크. | 바이오마커 및 치료 방법 |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| CN106008339B (zh) * | 2016-06-08 | 2018-09-07 | 上海准视生物科技有限公司 | 一种放射性c-met靶向亲和小分子化合物及其应用 |
-
2020
- 2020-06-08 EP EP20818373.1A patent/EP3980783A4/en not_active Withdrawn
- 2020-06-08 JP JP2021572340A patent/JP2022535880A/ja active Pending
- 2020-06-08 WO PCT/CN2020/094824 patent/WO2020244654A1/en not_active Ceased
- 2020-06-08 CA CA3142642A patent/CA3142642A1/en active Pending
- 2020-06-08 US US17/616,203 patent/US20220252603A1/en not_active Abandoned
- 2020-06-08 CN CN202080055590.1A patent/CN114599978A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020244654A5 (https=) | ||
| Awad et al. | Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis | |
| Drilon et al. | Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) | |
| Engstrom et al. | Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models | |
| Yau | Precision treatment in colorectal cancer: Now and the future | |
| Ellis et al. | VEGF-targeted therapy: mechanisms of anti-tumour activity | |
| Thomas et al. | Refining the treatment of NSCLC according to histological and molecular subtypes | |
| Kohno et al. | RET fusion gene: translation to personalized lung cancer therapy | |
| Maroto et al. | Molecular biomarkers in advanced renal cell carcinoma | |
| Zhu et al. | Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities | |
| Wang et al. | Identification of the MEK1 (F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-Raf V600E mutation | |
| Cerchietti et al. | Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas | |
| Cooper et al. | Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer | |
| CN107889463A (zh) | 用三种完全人类单克隆抗egfr抗体的组合治疗具有表皮生长因子受体（egfr）的胞外结构域的突变的患者的方法 | |
| Ohba et al. | Mutations of the EGFR, K-ras, EML4–ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma | |
| Lin et al. | Molecular testing for the treatment of advanced colorectal cancer: an overview | |
| Kilgoz et al. | KRAS and the reality of personalized medicine in non-small cell lung cancer | |
| van Geel et al. | Treatment individualization in colorectal cancer | |
| Nokin et al. | Targeting infrequent driver alterations in non-small cell lung cancer | |
| Rao et al. | A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers | |
| McKinnon et al. | Biomarker-informed care for patients with renal cell carcinoma | |
| Mauri et al. | Next-generation sequencing of circulating tumor DNA can optimize second-line treatment in RAS wild-type metastatic colorectal cancer after progression on anti-EGFR therapy: time to rethink our approach | |
| Huang et al. | The clinical significance of microsatellite instability in precision treatment | |
| Sulaiman et al. | Comprehensive Overview of Therapeutic Strategies in Colon Cancer: Chemotherapy, Targeted Therapy, and Immunotherapy | |
| Do et al. | Therapeutic targeting of cancer cells: era of molecularly targeted agents |